Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882990 | 0.92 | F2 (0.36) | PSMB5KMT2AMAPTGLAHPGD | |
| SCHEMBL5882552 | 0.91 | PSMB5 (0.37) | PSMB5KMT2AMAPTF10PRSS1 | |
| SCHEMBL5881897 | 0.86 | F2 (0.41) | KMT2AHPGDF10PRSS1PRSS2 | |
| SCHEMBL5881901 | 0.86 | F2 (0.41) | KMT2AHPGDF10PRSS1PRSS2 | |
| SCHEMBL5883615 | 0.86 | PSMB5 (0.35) | PSMB5KMT2AMAPTF10PRSS1 | |
| SCHEMBL5883612 | 0.86 | PSMB5 (0.35) | PSMB5KMT2AMAPTF10PRSS1 | |
| SCHEMBL5883029 | 0.85 | PRSS1 (0.35) | PSMB5F10PRSS1PRSS2F7 | |
| SCHEMBL5883024 | 0.85 | PRSS1 (0.35) | PSMB5F10PRSS1PRSS2F7 | |
| SCHEMBL5882403 | 0.85 | PSMB5 (0.35) | PSMB5KMT2AMAPTPRSS1PRSS2 | |
| SCHEMBL5883419 | 0.85 | SCN7A (0.37) | PSMB5KMT2AMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071212-B2 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1149069-B1 | PHENYLGLYCINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2004-02-19 | — | — | US | disclosed |
| US-6683215-B2 | TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION AND ARTERIOSCLEROSIS, WHICH ARE ASSOCIATED WITH COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA AND TISSUE FACTOR; ANTIINFLAMMATORY AGENTS | HOFFMAN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2003-05-01 | — | — | US | disclosed |
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034231-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | PSMB5 4326/4885KMT2A 3023/4885MAPT 1417/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | PSMB5 4326/4885KMT2A 3023/4885MAPT 1417/4885 |
| US-20030083504-A1 | N- (4-carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | PSMB5 4326/4885KMT2A 3023/4885MAPT 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.